Optimization of therapy in a patient with coronary heart disease in clinical practice: proven efficacy of the selective If channel inhibitor ivabradine

Cover Page

Cite item

Full Text

Abstract

The paper describes a clinical case of developing coronary heart disease in a young man, by analyzing the specific features of the disease and performed therapy. It discusses the management of this man according to the current recommendations and evidence-based medicine. The paper gives evidence for the importance of controlling heart rate in patients with angina pectoris. The most rational combinations of anti-ischemic agents for clinical application are discussed. Particular emphasis is laid on the selective If channel inhibitor ivabradine and its clinical effects: its good antianginal activity and ability to reduce the risk of cardiovascular events.

About the authors

M. G Bubnova

State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ

References

  1. Fihn S.D., Gardin J.M., Abrams J et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. JACC 2012; 60 (24): e44–164.
  2. Бокерия Л.А., Гудкова Р.Г. Сердечно - сосудистая хирургия. М.: Изд - во НЦССХ им. А.Н.Бакулева РАМН, 2010.
  3. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. и др. Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваскуляр. терапия и профилактика. 2010; 6: 47–56.
  4. Ипатов П.В., Кротов А.В., Бойцов С.А. Первая помощь при неотложных состояниях с использованием карманных аптечек. Медицина неотложных состояний. 2009; 3–4: 22–3.
  5. Гафаров В.В., Благинина М.Ю. Смертность от острого инфаркта миокарда (эпидемиологическое исследование на основе программ ВОЗ «Регистр острого инфаркта миокарда, МОНИКА»). Кардиология. 2005; 5: 49–51.
  6. Аронов Д.М. Коронарная недостаточность у молодых. М.: Медицина, 1974.
  7. Карпов Ю.А., Сорокин Е.В. Стабильная ишемическая болезнь сердца. Медицинское информационное агентство. 3-е изд. М., 2012; с. 208–12.
  8. Dahlen G.H., Guyton J.R., Attar M et al. Association of levels of lipoprotein (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758–65.
  9. Assman G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle - aged men. Am J Cardiol 1996; 77: 1179–84.
  10. Dahlen G.H. Lp(a) lipoprotein in cardiovascular disease. Review and new point. Atherosclerosis 1994; 108: 111–26.
  11. Steg Ph.G., James S.K., Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J; doi: 10.1093/eurheart/ehs215.
  12. Заключение Совета экспертов российских обществ. Оптимизация терапии статинами пациентов высокого и очень высокого сердечно - сосудистого риска. CardioCоматика 2011; 4: 87.
  13. Fox K, Garcia M.A.A., Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1334–81.
  14. Patel S.R., Breall J.A., Diver D.J., Levy A.P. Bradycardia is associated with development of coronary collateral vessels in humans. Coron Artery Dis 2000; 11: 467–71.
  15. Pratt C.M., Mc Mahon R.P., Goldstein S et al. Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia [the Asymptomatic Cardiac Ischemia Pilot (ACIP) study]. Am J Cardiol 1996; 77: 1302–9.
  16. Kolloch R, Legler U.F., Champion A et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease findings from the International VErapamil-SR/trandalopril Study (INVEST). Eur Heart J 2008; 29: 1327–34.
  17. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Heart rate a prognostic risk factor in patients with coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized, controlled trial. Lancet 2008; doi: 10.1016/S-140-6736(08)61171-X.
  18. Шальнова С.А., Деев А.Д., Оганов Р.Г. Частота пульса и смертность от сердечно - сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология. 2005; 10: 45–50.
  19. Persky A, Olsson G, Laudou C et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 606–16.
  20. Heidland U.E., Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104 (13): 1477–82.
  21. Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180–2.
  22. Сustodis F, Baumhaekel M, Schlimmer N et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008; 117: 2377–87.
  23. Hjalmarson A, Gilpin E, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infection. Am J Cardiol 1990; 65: 547–53.
  24. Zuanetti G, Hernandez-Bernal F, Rossi A et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction the GISSI experience. Eur Heart J 1999; 1 (Suppl. H): H52–H57.
  25. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post - myocardial infarction: a meta - regression of randomized clinical trials. Eur Heart J 2007; 28: 3012–9.
  26. Parodi G, Bellandi B, Valenti R et al. Heart rate as an independent prognostic risk factor in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Atherosclerosis 2010; 211: 255–9.
  27. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomized, double - blind, placebo - controlled trial. Lancet 2008; 37: 807–16.
  28. Colin P, Ghaleh B, Monnet X et al. Contributions of heart and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: H676–H682.
  29. Simon L, Gheleh B, Puybasset L et al. Coronary and hemodynamic effects of S 16257, a new bradycardiac agent, in resting and exercising conscious dog. J Pharmacol Exp Ther 1995; 275: 659–66.
  30. Vilaine J.P., Thollon C, Villeneuve N et al. Procoralan, a new selective If current inhibitor. Eur Heart J 2003; 5 (Suppl. G): G26–35.
  31. Tardif J.C., Ford I, Tendera M, Bourassa M.G. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with stable angina. Eur Heart J 2005; 26: 2529–36.
  32. Ruzyllo W, Ford I, Tendera M et al. Antianginal and anti - ischemic effects of ivabradine compared to amlodipine in patients with stable effort angina: a 3-month randomized, double - blind,, multicentre, noninferiority trial. Drugs 2007; 67: 393–405.
  33. Tendera M, Bores J, Tardif J.C. Efficacy of If Inhibition with Ivabradine in Different Subpopulations with Stable Angina Pectoris. Cardiology 2009; 114: 116–25.
  34. Fox K, Ford L, Steg P.G. et al. On behalf of the BEAUTIFUL Investigators. Relationship between ivabradine and cardiovascular outcomes in patients with stable coronary artery disease and left - ventricular systolic dysfunction with limiting angina: a subgroup analysis of a randomized, controlled BEAUTIFUL trial. Eur Heart J; doi: 10.1093/eurheart/ehp358.
  35. Tardif J.C., Berry C. From coronary artery disease to heart failure: potential benefits of ivabradine. Eur Heart J 2006; 8 (Suppl. D): D24–D29.
  36. Fox K.M., Mulcahy D, Findlay I et al. TIBET Study Group The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR, and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96–103.
  37. Savonitto S, Ardission D, Egstrup K et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of international multicenter angina exercise (IMAGE) study. J Am Coll Cardiol 1996; 27: 311–6.
  38. Klein W.W., Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris. Coron Artery Dis 2002; 13: 427–36.
  39. Knight C, Fox K.M. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Study in Angina Research (CESAR) Investigators. Am J Cardiol 1998; 81: 133–6.
  40. Pehrsson S.K., Ringqvist I, Ekdahl S et al. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol 2000; 23: 763–70.
  41. Tardif J.,. Ponikowski P, Kahan T. For the ASSOCIATE. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta - bloker therapy: a 4-month, randomized, placebo - controlled trial. Eur Heart J 2009; 30: 440–8.
  42. Глезер М.Г., Сайгитов Р.Т. от имени участников исследования КОНТРОЛЬ. Антиангинальная эффективнсть и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ (Кораксан в комбинированной терапии с бета - адреноблокаторами у пациентов со стабильной стенокардией. Антиангинальная эффективность и переносимость). Кардиология. 2010; 11: 65–75.

Copyright (c) 2013 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies